DefinitionThis section has been translated automatically.
Genetically engineered, humanized, monoclonal IgG1 kappa antibody that binds specifically to the 21- to 28-kDa glycoprotein CD52 on the cell surface of lymphocytes. CD52 is a surface antigen that is expressed by B and T lymphocytes. The antibody is produced in a suspension culture from mammalian cells (Chinese hamster ovary cells).
IndicationThis section has been translated automatically.
Chronic lymphatic leukemia (CLL), Sézary syndrome. Indication is given in the absence of or insufficient improvement on the administration of alkylants and nucleoside analogues such as Fludarabine. Alemtuzumab shows a good response rate in pre-treated patients and may prolong the mean survival time. However, it does not offer a curative therapeutic approach, just as conventional cytostatic drugs do not.
You might also be interested in
Dosage and method of useThis section has been translated automatically.
Maintenance doses of 30 mg 3 times/week have been indicated for CLL to date. The average duration of therapy is 12 months. In Sézary syndrome, a "low-dose" therapy concept with 3 times/week 15 mg was successfully applied (due to the still high infection complication rate, a dosage of 3 times/week 10 mg is recommended).
Undesirable effectsThis section has been translated automatically.
Severe hemologic toxicity (grade 3-4 cytopenia up to 45%), increased risk of infectious complications (bacterial sepsis).
PreparationsThis section has been translated automatically.
MabCampath
LiteratureThis section has been translated automatically.
- Bernengo MG et al Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunological findings in 14 patients. Haematologica 92: 785-792
Prof. Dr. med. Peter Altmeyer